R&D | November 25, 2025
Alzheimer’s testing goes painless, homebound with Neurogen-Tasso partnership
The collaboration aims to make Alzheimer’s biomarker testing more accessible and less intimidating
The collaboration aims to make Alzheimer’s biomarker testing more accessible and less intimidating
Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1
Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation
Contera Pharma will receive an upfront payment and full research funding for each target under investigation
The positive opinion is based on results from KOMET, the largest and only placebo-controlled, double-blind global Phase III trial in this patient population
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
Sensory Boxes include items such as drawing boards and fidget balls to support management of anxiety and improve shopping experience
The centre is equipped with the most modern tools and provides an environment soothing for all professionals and patients
Lenire is the first and only bimodal neuromodulation device to be awarded a Federal Supply Schedule (FSS) Contract from the US Government
Subscribe To Our Newsletter & Stay Updated
